Elona Juozaitytė

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer

Stephen Chan, N. Davidson, Elona Juozaitytė et al. · Annals of Oncology · 2004 · 149 citations

Metastatic Breast Cancer, Oncology, Breast Oncology +9

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Thomas Bachelot, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2019 · 111 citations · Full text

Metastatic Breast Cancer, Breast Oncology, Medicine +7

Initial results of a randomized controlled trial comparing clinical and pathological downstaging of rectal cancer after preoperative short‐course radiotherapy or long‐term chemoradiotherapy, both with delayed surgery

Tadas Latkauskas, Henrikas Paužas, Irina Gineikienė et al. · Colorectal Disease · 2011 · 108 citations

Lack of association between gene polymorphisms of Angiotensin converting enzyme, Nod-like receptor 1, Toll-like receptor 4, FAS/FASL and the presence of Helicobacter pylori-induced premalignant gastric lesions and gastric cancer in Caucasians

Juozas Kupčinskas, Thomas Wex, Jan Bornschein et al. · BMC Medical Genetics · 2011 · 79 citations · Full text